article thumbnail

Early-stage biotech investment: where are we? 

Drug Discovery World

Where is the market at? When companies think about raising investment, the UK, EU and US are very popular markets for obvious reasons, but spreading the net wider can be a smart strategy. Be accurate about where your IP fits into the market and how you’re going to commercialise the technology.

Packaging 147
article thumbnail

Animals Need Drugs Too, But Not Without CVM Approval

FDA Law Blog: Biosimilars

Palmer & Riëtte van Laack — Most of us love our furry friends, and with the boom in pet ownership during the pandemic, it is no surprise that the market for pet products has become enormous. CVM does not regulate the practice of veterinary medicine (that’s a state licensing board) or vaccines for animal diseases (that’s USDA).

FDA 59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Nine Key Takeaways from Dreamforce 2023

Perficient: Drug Development

Increased Capabilities for Marketing Cloud and Commerce Cloud Salesforce introduced 26 generative AI capabilities between Marketing Cloud and Commerce Cloud, 14 of which are in GA now, with an additional 14 to arrive by the end of 2024.

article thumbnail

Using Rapid Development Environment in AEM as a Cloud Service

Perficient: Drug Development

Depending on the size of the team and anticipated activity within a program, additional RDEs can also be provisioned, however, this may come at an additional licensing cost from Adobe. In this simple example, a content package is deployed with the aio aem:rde :install command.

Packaging 105
article thumbnail

Proposals for changes to EU pharma legislation raise concerns for SMEs

Drug Discovery World

The EC also says that earlier availability of generic and biosimilar medicines will be facilitated, and market authorisation procedures simplified. The EC also proposes to abolish (in most cases) marketing authorisation renewal and introduce simpler procedures for generic medicines.

article thumbnail

European Commission vs Big Pharma, or profit vs access?  

Drug Discovery World

Regulatory data protection (RDP) period RDP refers to the time when generic drug makers cannot refer to an innovator drug’s data to obtain a marketing authorisation 2. According to EFPIA, RDP protects an innovator’s investment by granting a limited period of exclusivity on the data it generated, starting from marketing authorisation 4.

article thumbnail

Making Sense of Sitecore’s Headless Options

Perficient: Drug Development

Usually, Sitecore Headless Services can be implemented using the current licensing model, providing a seamless transition for existing Sitecore users, however we have seen clients on perpetual licenses need to negotiate with Sitecore to add this capability to their license. XM Cloud is where Sitecore is innovating.